Učitavanje...
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma
Early results of a prospective phase 2 clinical trial of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance in high-risk smoldering myeloma showed promising results that were previously published. Here, we provide novel insights into the genetic landscape of high-risk...
Spremljeno u:
| Izdano u: | Blood Adv |
|---|---|
| Glavni autori: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5728141/ https://ncbi.nlm.nih.gov/pubmed/29296837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017005934 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|